{"id":"W2009611159","doi":"10.1111/ijcp.12433","title":"Safety and tolerability of the β<sub>3</sub>‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial","year":2014,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Allergan; Astellas Pharma; Astellas Foundation for Research on Metabolic Disorders; Pfizer; Coloplast; Ipsen; Teva Pharmaceutical Industries","keywords":"Tolerability; Mirabegron; Medicine; Overactive bladder; Placebo; Tolterodine; Adverse effect; Urology; Internal medicine; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01675473,0.0002053691,0.002844817,0.0002309262,0.00006534158,0.0000186118,0.0002692225,0.0001346416,0.00005631167],"category_scores_gemma":[0.05475696,0.0001100189,0.001480846,0.0002555567,0.0007309953,0.0002423175,0.00006055045,0.0003630338,9.098963e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007243962,"about_ca_system_score_gemma":0.0006653961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001633063,"about_ca_topic_score_gemma":0.00004377063,"domain_scores_codex":[0.9912838,0.002125352,0.004986,0.0002905288,0.001161911,0.0001524481],"domain_scores_gemma":[0.9263387,0.06258515,0.007460245,0.0003678616,0.003100367,0.0001476963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9162842,0.01168351,0.0006061418,0.00005076111,0.02623671,0.00000588704,0.001367595,0.00004196682,0.01147447,0.00006981576,0.00006805514,0.03211086],"study_design_scores_gemma":[0.9019465,0.02270924,0.007170176,0.0001407851,0.0164483,0.00002441061,0.0005701894,0.001932683,0.04799238,0.000410228,0.000566692,0.00008838268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883465,0.0005664574,0.00294647,0.002868096,0.000334889,0.003849513,0.000709604,0.000002112109,0.0003763199],"genre_scores_gemma":[0.9966972,0.002321512,0.0005058713,0.00003833049,0.0003442764,0.00003166705,0.00002059815,0.00001258097,0.00002796078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06494507,"threshold_uncertainty_score":0.9532052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08926726579271346,"score_gpt":0.4568707791945406,"score_spread":0.3676035134018271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}